Alto Neuroscience ANRO
- Market cap
- $870.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −7.9%
Alto Neuroscience's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $8M | $9.6M | $10M+77% | $13.2M+86% | $13.1M+64% | $10.8M+12% | $10M+0% | $13.1M−1% | $10.5M−19% | $12M+11% | $20.3M+104% | $22.1M+69% |
| SG&A | $1.8M | $2.1M | $4.4M+179% | $5.2M+151% | $5.8M+233% | $6.2M+192% | $5.7M+29% | $5.6M+8% | $4.4M−24% | $5.1M−18% | $6.8M+20% | $7M+26% |
| −$9.7M | −$11.8M | −$14.4M+100% | −$18.3M+101% | −$18.9M+94% | −$17M+45% | −$15.7M+9% | −$18.7M+2% | −$15M−21% | −$17.1M+0% | −$27.1M+73% | −$29.1M+56% | |
| Interest expense | $363K | $356K | $346K+7% | $347K+6% | $349K−4% | $333K−7% | $598K+73% | $646K+86% | $650K+86% | $575K+73% | $545K−9% | $491K−24% |
| Net income | −$9.1M | −$11.2M | −$13.4M+84% | −$16M+85% | −$16.8M+84% | −$15.2M+36% | −$15.2M+13% | −$17.7M+11% | −$14.2M−16% | −$16.2M+7% | −$26.2M+73% | −$27.6M+56% |
| −$2.44 | −$2.97 | −$0.76−61% | −$0.60−74% | −$0.62−75% | −$0.57−81% | −$0.56−26% | −$0.65+8% | −$0.52−16% | −$0.47−18% | −$0.80+43% | −$0.65+0% | |
| 3.7M | 3.8M | 17.6M+377% | 26.9M+624% | 27M+620% | 26.8M+609% | 27M+54% | 27.1M+1% | 27.1M+1% | 34.1M+28% | 32.9M+22% | 42.8M+58% |
EPS, diluted: 3 periods, Q4 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Alto Neuroscience's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ANROAlto Neuroscience | $870.8M | n/m | n/a | n/m | n/m | n/m | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| Peer median | $781.2M | 13.8× | 17.0× | 1.8× | +6% | 11.2% |
More on Alto Neuroscience
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .